Cargando…

Ibrutinib and novel BTK inhibitors in clinical development

Small molecule inhibitors targeting dysregulated pathways (RAS/RAF/MEK, PI3K/AKT/mTOR, JAK/STAT) have significantly improved clinical outcomes in cancer patients. Recently Bruton’s tyrosine kinase (BTK), a crucial terminal kinase enzyme in the B-cell antigen receptor (BCR) signaling pathway, has eme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akinleye, Akintunde, Chen, Yamei, Mukhi, Nikhil, Song, Yongping, Liu, Delong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751776/ https://www.ncbi.nlm.nih.gov/pubmed/23958373 http://dx.doi.org/10.1186/1756-8722-6-59

Ejemplares similares

STAT inhibitors for cancer therapy
por: Furqan, Muhammad, et al.
Publicado: (2013)

MEK and the inhibitors: from bench to bedside
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Novel ALK inhibitors in clinical use and development
por: Iragavarapu, Chaitanya, et al.
Publicado: (2015)

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Ibrutinib for B cell malignancies
por: Novero, Aileen, et al.
Publicado: (2014)

Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner
por: Liu, Jia, et al.
Publicado: (2022)

Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies
por: Zhu, Sining, et al.
Publicado: (2021)

Novel agents for advanced pancreatic cancer
por: Akinleye, Akintunde, et al.
Publicado: (2015)

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL
por: Sharma, Shruti, et al.
Publicado: (2016)

A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells
por: Natarajan, Gayathri, et al.
Publicado: (2016)

Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer
por: Zhu, Zhen, et al.
Publicado: (2020)

Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application
por: Furqan, Muhammad, et al.
Publicado: (2013)

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
por: Wu, Jingjing, et al.
Publicado: (2016)

Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer
por: Zucha, Muhammad Ary, et al.
Publicado: (2015)

Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis
por: Colado, Ana, et al.
Publicado: (2018)

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients
por: Treon, Steven P., et al.
Publicado: (2020)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia
por: de Porto, Alexander P., et al.
Publicado: (2019)

Ibrutinib directly reduces CD8+T cell exhaustion independent of BTK
por: Li, Ling, et al.
Publicado: (2023)

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
por: Akinleye, Akintunde, et al.
Publicado: (2019)

Current management and novel agents for malignant melanoma
por: Lee, Byung, et al.
Publicado: (2012)

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
por: Nicolson, Phillip L.R., et al.
Publicado: (2018)

Effect and Mechanism of the Bruton Tyrosine Kinase (Btk) Inhibitor Ibrutinib on Rat Model of Diabetic Foot Ulcers
por: Yang, Xuedong, et al.
Publicado: (2019)

Current and novel BTK inhibitors in Waldenström’s macroglobulinemia
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2021)

Controlling Ibrutinib’s Conformations about Its Heterobiaryl Axis to Increase BTK Selectivity
por: Toenjes, Sean T., et al.
Publicado: (2023)

Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes
por: Zhu, Sining, et al.
Publicado: (2021)

Novel CD20 monoclonal antibodies for lymphoma therapy
por: Cang, Shundong, et al.
Publicado: (2012)

Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice
por: Schutt, Steven D., et al.
Publicado: (2015)

Ibrutinib facilitates the sensitivity of colorectal cancer cells to ferroptosis through BTK/NRF2 pathway
por: Zhu, Jin-Feng, et al.
Publicado: (2023)

The Development of BTK Inhibitors: A Five-Year Update
por: Tasso, Bruno, et al.
Publicado: (2021)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
por: Bonfiglio, Silvia, et al.
Publicado: (2023)

Novel agents for chronic lymphocytic leukemia
por: Wu, Mei, et al.
Publicado: (2013)

Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes
por: Wei, Li, et al.
Publicado: (2016)

Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
por: Arthur, Rachael, et al.
Publicado: (2020)

Ibrutinib Prevents Acute Lung Injury via Multi-Targeting BTK, FLT3 and EGFR in Mice
por: Rao, Huanan, et al.
Publicado: (2022)

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
por: Cang, Shundong, et al.
Publicado: (2015)

The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma
por: Pal, Dhananjaya, et al.
Publicado: (2021)

BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib
por: Estupiñán, H. Yesid, et al.
Publicado: (2021)

Managing Waldenström’s macroglobulinemia with BTK inhibitors
por: Buske, Christian, et al.
Publicado: (2022)

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
por: Qi, Jialei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3gek4mi4m45a4b6hjmnn2a7214